These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36910619)

  • 1. The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials.
    Fisher A; Goradia H; Martinez-Calle N; Patten P; Munir T
    Front Oncol; 2023; 13():1130617. PubMed ID: 36910619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
    Cheson BD; Mato AR
    Clin Adv Hematol Oncol; 2020 Jun; 18 Suppl 10(6):1-20. PubMed ID: 33843867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis.
    Rios-Olais FA; McGary AK; Tsang M; Almader-Douglas D; Leis JF; Buras MR; Hilal T
    JAMA Oncol; 2024 Sep; 10(9):1221-1227. PubMed ID: 38990562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
    Thompson M; Brander D; Nabhan C; Mato A
    JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
    Fürstenau M; De Silva N; Eichhorst B; Hallek M
    Hemasphere; 2019 Oct; 3(5):e287. PubMed ID: 31942542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
    Rios-Olais FA; Hilal T
    Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
    Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
    Front Oncol; 2019; 9():689. PubMed ID: 31555576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable residual disease in chronic lymphocytic leukemia.
    Benintende G; Pozzo F; Innocenti I; Autore F; Fresa A; D'Arena G; Gattei V; Lurenti L
    Front Oncol; 2023; 13():1112616. PubMed ID: 36865804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease in the treatment of chronic lymphocytic leukemia.
    Uchiyama T; Yokoyama A; Aoki S
    J Clin Exp Hematop; 2020 Dec; 60(4):138-145. PubMed ID: 33148932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
    Stumpf J; Al-Sawaf O
    Curr Oncol Rep; 2024 Feb; 26(2):136-146. PubMed ID: 38175465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
    JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRD-directed therapy in CLL: ready for prime time?
    Rhodes JM; Lopez CA; Barrientos JC
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):413-420. PubMed ID: 38066928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting progression-free survival from measurable residual disease in chronic lymphocytic leukemia.
    Tettamanti FA; Kimko H; Sharma S; Di Veroli G
    Clin Transl Sci; 2024 Aug; 17(8):e13905. PubMed ID: 39164859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
    Thompson PA; Wierda WG
    Blood; 2016 Jan; 127(3):279-86. PubMed ID: 26576865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C
    Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):423-430. PubMed ID: 31027992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eradication of minimal residual disease in chronic lymphocytic leukemia.
    Schweighofer CD; Hallek M; Wendtner CM
    Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.